Gene Therapy Workshop

Date: October 5, 2019 @ 1:00 pm – @ 6:00 pm
Location: Hanhai BioLabs (1633 Bayshore Highway, Suite 280, Burlingame, CA 94010)

Agenda:

1:00 to 1:20 PM Check-in and networking.

1:20 to 1:30 PM Welcome remarks from CABS.

1:30 to 2:15 PM Lentivirus in Gene Therapy. Gary Li, PhD, Founder and CEO, ALSTEM.

2:15 to 3:00 PM The Development of AAV Manufacturing Technologies: From the Traditional to the Advanced.Haifeng Chen, PhD, CEO, Virovek, Inc.

3:00 to 3:15 PM Break.

3:15 to 4:00 PM Manufacturing Clinical AAVs at Scale for Gene Therapy – Scary Task for the Success. Kee-Hong Kim,PhD, Senior Vice President, Manufacturing & Technical Operations, Tenaya Therapeutics.

4:00 to 4:45 PM Gene Therapy: Hopes and Challenges. Shengjiang Liu,PhD, Chief Scientist and Head (VP) of Global Pathogen Safety of Product Supply-Biologics, Bayer Pharmaceuticals.

4:45 to 5:30 PM Refreshment & Networking.


Speakers Background:

Dr. Gary Li is the Founder and CEO of ALSTEM. With 20 years of active research experience Dr. Li is an expert in the fields of stem cell technology, neuroscience, and biochemistry with a successful academic publication record.  He is experienced in the pharmaceutical industry in the United States, and also the owner of several patents on the treatment of neurodegenerative disorders. 

Dr. Li received his PhD degree from Nanjing Universityand his post-doctoral training in stem cell and neuroscience at Gladstone Institute, UCSF supported by California Institute for Regenerative Medicine (CIRM).  Because of his contributions to neurodegenerative study, Dr. Li received the “Kathryn Grupe Award for Excellence in Alzheimer's Research” from the Alzheimer's Association.  Dr. Li also serves as the vice present at the Chinese Stem Cell Foundation. He is also a member of several professional societies. Dr. Li is a joint faculty of Bioengineering Department at Santa Clara University.


Dr. Haifeng Chen, CEO, Virovek, Inc., obtained his PhD from Saarland University in 1992 and awarded the Marion-Merrell-Dow Post-Doctoral Fellowship to perform research on adenovirus replication at the University of Kansas Medical Center in Kansas City, Kansas. From 1996 to 2006 he worked in several gene therapy companies including Cell Genesys, Genovo, Avigen, and Asklepois Biopharmaceuticals and obtained rich experiences in the gene therapy field. Afterwards he founded his own company, Virovek, to provide AAV vector production services to the academic and biopharmaceutical research communities. He has invented several novel technologies for large-scale AAV vector production and purification. Under his leadership, Virovek has now developed the capacity to provide purified AAV vectors exceeding 1 x 1017vg scale per production run. Dr. Chen is currently a committee member of the Viral Gene Transfer Vector Committee of American Society of Gene and Cell Therapy (ASGCT). He is also a member of Society for Neuroscience (SfN) and American Association for Cancer Research (AACR).

Dr. Kee-Hong Kim, Senior Vice President, Manufacturing & Technical Operations, Tenaya Therapeutics, was most recently Senior Vice President, Head of Technical Operations at Agilis Biotherapeutics, where he had accountability for manufacturing of gene therapy drug products, as well as establishing reliable clinical and commercial supply chains. Prior to that, he was the Head of the Gene Therapy Process Development, and the global CMC Lead of Gene Therapy at Shire. Dr. Kim also ran his own biopharma consulting firm, which he started after serving as Director of Process Development at Avalanche Biotechnology. Dr. Kim was responsible for the 2nd Generation Commercial Process Development at Dendreon Corp. and the Manufacturing Science & Technology and application of sBLA/MAA of the commercial product PROVENGE™. Prior to Dendreon, Dr. Kim had roles of increasing leadership at several technical organizations including Aeras TB Foundation (Rockville, MD) and Walter Reed Army Medical Center (Rockville, MD). He completed his post-doctoral training at Cornell University, and received his doctoral degree in Chemical Engineering from Colorado State University.

Dr. Shengjiang Liu (Ph.D., DVM) is an experienced biotechnologist, entrepreneur and investor of early stage ventures in high technology and biotechnology. He is the chief scientist and head (VP) of Global Pathogen Safety of Product Supply-Biologics, Bayer Pharmaceuticals since 2006. He serves as a director in several startup companies since 2007. Dr. Liu is the president and cofounder of the California Chinese Biotech/Biopharma Entrepreneur Association (CCBEA).  He is also an Industrial Advisory Board Member of Bioengineering in Santa Clara University and a mentor of Techcode (Taiku, Mountain View, CA), an active member in BPOG Biophorium (UK), Parental Drug Association (PDA) and World Federation of Hemophilia (WFH).

Dr. Liu was a founder and president of Abmaxis Inc. (acquired by Merck, 2006). He was a group leader of Genentech Inc. in 1990s and assistant professor in Nanjing Agricultural University (NAU) where he investigated animal virology and immunology. He discovered rabbit hemorrhagic disease virus (RHDV), rabbit calicivirus (RC) and the new rabbit disease in 1984 when he was in China. Dr. Liu has been a key player in 33 biologics including recombinant factor VIII (rhFVIII), Kovartry, long acting rhFVIII (Jivi) therapeutic antibody drug development and 10 biological license approvals in the past 23 years. He plays an important role AAV-FVIII development for human hemophilia A gene therapy. 

Dr. Liu received his Ph.D. of biochemistry from Kansas State University. He completed his post-doctor training with Dr. Arthur Kornberg, Stanford University.

 

Gene Therapy Workshop – $0 (USD)